Who are Usual DMT continuation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clozaril, Risperdal,reminyl, risperidone (Risperdal), Quetiapine or Risperidone + Aripiprazole, sodium valproate with Clozapine, Any FDA approved antipsychotic agent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/usual-dmt-continuation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Usual DMT continuation — Competitive Intelligence Brief

Usual DMT continuation (Usual DMT continuation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor agonist. Area: Psychiatry.

phase 3 Serotonin receptor agonist 5-HT2A Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Usual DMT continuation (Usual DMT continuation) — University Hospital, Strasbourg, France. DMT acts as a potent agonist at the serotonin 5-HT2A receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Usual DMT continuation TARGET	Usual DMT continuation	University Hospital, Strasbourg, France	phase 3	Serotonin receptor agonist	5-HT2A
Clozaril	CLOZAPINE	Jazz Pharmaceuticals	marketed	Atypical Antipsychotic [EPC]	D2, 5-HT2A	1989-01-01
Risperdal,reminyl	Risperdal,reminyl	Jinan Mental Hospital	marketed	Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl)	Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
risperidone (Risperdal)	risperidone (Risperdal)	University of South Florida	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine or Risperidone + Aripiprazole	Quetiapine or Risperidone + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase
Any FDA approved antipsychotic agent	Any FDA approved antipsychotic agent	Vanguard Research Group	marketed	Antipsychotic (dopamine antagonist)	Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-01 — Clozaril · 8057811 · Formulation · US

Sponsor landscape (Serotonin receptor agonist class)

Addpharma Inc. · 1 drug in this class
Organon and Co · 1 drug in this class
Serenity Pharmaceuticals, Inc. · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Usual DMT continuation — Competitive Intelligence Brief. https://druglandscape.com/ci/usual-dmt-continuation. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab